SCHEMBL19638080

SCHEMBL19638080

CC(C)(C)OC(=O)n1ccc(C(=O)O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
BCHE P06276 1/20 0.37
MAPT P10636 1/20 0.37
BUB1 O43683 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
ELANE P08246 1/20 0.34
SRD5A2 P31213 1/20 0.33
GRM5 P41594 1/20 0.33
GRM1 Q13255 1/20 0.33
ABCB1 P08183 1/20 0.33
ABL1 P00519 1/20 0.33
RIN1 Q13671 1/20 0.33
ESR2 Q92731 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7023132 0.83 NR1H2 (0.41) KMT2AMEN1BCHEMAPTPKM
SCHEMBL7014583 0.80 CA12 (0.42) KMT2AMEN1MAPTESR2ALDH1A1
SCHEMBL11911366 0.79 GPR119 (0.39) GPR119KMT2AMEN1BCHEMAPT
SCHEMBL7528678 0.79 ESR2 (0.40) GPR119KMT2AMEN1BCHEMAPT
SCHEMBL7370834 0.79 MEN1 (0.34) GPR119KMT2AMEN1BCHEBUB1
SCHEMBL12593934 0.77 NR1H2 (0.41) GPR119KMT2AMEN1BCHEBUB1
SCHEMBL1018306 0.77 BCHE (0.38) GPR119KMT2AMEN1BCHEMAPT
SCHEMBL28581988 0.77 BCHE (0.38) GPR119KMT2AMEN1BCHEMAPT
SCHEMBL20033881 0.77 BCHE (0.38) GPR119KMT2AMEN1BCHEMAPT
Hydrochloric Acid SCHEMBL28584468 0.76 BCHE (0.37) GPR119KMT2AMEN1BCHEMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105924379-A Preparation method of 1-BOC-3-hydroxymethyl pyrrolidine 苏州艾缇克药物化学有限公司 2016-09-07 CN claimed
CN-119823103-A Polycyclic derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2025-04-15 CN disclosed
CN-119219608-A Polycyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-12-31 CN disclosed
EP-3248980-B1 JAK INHIBITOR WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) 2023-09-06 EP disclosed
CN-111518096-B Janus kinase JAK family inhibitor and preparation and application thereof 江苏威凯尔医药科技有限公司 2022-02-11 CN disclosed
CN-108349977-B JAK inhibitors 无锡福祈制药有限公司 2021-05-25 CN disclosed
CN-111518096-A Janus kinase JAK family inhibitor and preparation and application thereof 江苏威凯尔医药科技有限公司 2020-08-11 CN disclosed
US-10617690-B2 JAK inhibitor Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2020-04-14 US disclosed
CN-108349977-A Jak inhibitor 无锡福祈制药有限公司 2018-07-31 CN disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 US disclosed
EP-3248980-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-11-29 EP disclosed
CN-105924379-A Preparation method of 1-BOC-3-hydroxymethyl pyrrolidine 苏州艾缇克药物化学有限公司 2016-09-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360794-A1 JAK INHIBITOR JAK2, JAK1, JAK3 GPR119 1493/4885KMT2A 665/4885MEN1 2985/4885
US-10617690-B2 JAK inhibitor JAK2, JAK1, JAK3 GPR119 1493/4885KMT2A 665/4885MEN1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.